Radiotherapy Utilization Patterns Among Patients With Metastatic Renal Cell Carcinoma of the Spine
From 2010 to 2023, EBRT remained the predominant first-line radiotherapy for spinal mRCC. Higher commercial insurance rates among SBRT recipients and regional variability in SBRT use suggest that payer mechanisms and institutional variation may influence first-line SBRT use. Policy alignment with contemporary evidence and expansion of SBRT infrastructure may enhance patient access.
Authors
- Emanuel Ray (ORCID: https://orcid.org/0000-0002-1528-5825)
- Trey C. Mullikin (ORCID: https://orcid.org/0000-0002-1099-1763)
- Emily Luo (ORCID: https://orcid.org/0000-0003-2237-3521)
- Joshua Woo (ORCID: https://orcid.org/0000-0002-2849-2604)
- Nicole Rivera
- Kerri-Anne Crowell
- Ramzy Ahmed
- Melissa Erickson
- Eli Johnson
- Tobechukwu C. Ndika
- C. Rory Goodwin
Institutions
- Duke University (US)
- Cancer Institute (WIA) (IN)
- Duke Medical Center (US)
- Radiation Oncology Associates (US)
- Duke Cancer Institute
Publication Details
- Journal
- American Journal of Clinical Oncology
- Published
- 2026-03-13
- DOI
- https://doi.org/10.1097/coc.0000000000001318
- Primary Topic
- Management of metastatic bone disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00